Sanofi Genzyme starts phase 3 trial of second-generation enzyme replacement therapy for Pompe disease

Sanofi Genzyme, the specialty care global business unit of Sanofi, has started a pivotal Phase 3 clinical trial named COMET for the investigational therapy neoGAA for Pompe Disease.
Read the full story: PBR - Clinical Trials News